Comparative Pharmacology
Head-to-head clinical analysis: AUROVELA FE 1 5 30 versus BREVICON 21 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUROVELA FE 1 5 30 versus BREVICON 21 DAY.
AUROVELA FE 1.5/30 vs BREVICON 21-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing norethindrone acetate and ethinyl estradiol. Norethindrone acetate is a progestin that suppresses gonadotropin release, inhibiting ovulation; ethinyl estradiol is an estrogen that provides feedback inhibition of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), preventing follicular development and ovulation. Additionally, it causes changes in cervical mucus (increased viscosity) and endometrium (reduced receptivity).
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin (FSH, LH) release via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation. Increases viscosity of cervical mucus and alters endometrial lining to impede sperm penetration and implantation.
One tablet orally once daily at the same time each day for 28 consecutive days.
One tablet (0.5 mg norethindrone and 0.035 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days off.
None Documented
None Documented
Norethindrone: 5-14 hours (terminal); Ethinyl estradiol: 10-20 hours (terminal). Steady-state achieved within 5-7 days; contraceptive efficacy maintained with daily dosing.
Norethindrone: 7-8 hours; Ethinyl estradiol: 13-17 hours. Clinical context: Steady state reached within 5-7 days; missed pills may reduce contraceptive efficacy.
Renal: ~50-60% as metabolites, <10% unchanged; Fecal: ~40-50% via bile; Ethinyl estradiol undergoes enterohepatic recirculation.
Urine (50-60% as metabolites, <10% unchanged); feces (30-40% as metabolites); biliary (minor).
Category C
Category C
Oral Contraceptive
Oral Contraceptive